The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin

Clinical Endocrinology

Volumn 50, Issue 1, 1999, Pages 77-84

  Rahim, A ^a   O'Neill, P A ^b   Shalet, S M ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; DEOXYPYRIDINOLINE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; GROWTH HORMONE RELEASING FACTOR; HEXARELIN; HORMONE BINDING PROTEIN; HUMAN GROWTH HORMONE; HYDROCORTISONE; IBUTAMOREN; OSTEOCALCIN; PLASMA PROTEIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROLACTIN; PYRIDINOLINE; THYROTROPIN; THYROXINE;

ADRENAL FUNCTION; AGED; ARTICLE; BLOOD CHEMISTRY; BODY COMPOSITION; BONE MINERAL; CLINICAL ARTICLE; CORTICOTROPIN RELEASE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG SAFETY; FEMALE; HORMONAL REGULATION; HORMONE DETERMINATION; HORMONE RESPONSE; HUMAN; HYDROCORTISONE RELEASE; HYPERPHAGIA; HYPOPHYSIS ADRENAL SYSTEM; LONG TERM CARE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROLACTIN RELEASE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; OLIGOPEPTIDES; PITUITARY-ADRENAL SYSTEM; PROLACTIN; TIME FACTORS;

EID: 0032993995     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.1999.00609.x     Document Type: Article

References (21)

1. Arvat, E., Gianotti, L., Broglio. F., Maccagno, B., Bertagna, A., Deghenghi, R., Camanni, F., & Ghigo, E. (1997) Oestrogen replacement does not restore the reduced GH-releasing activity of Hexarelin, a synthetic hexapeptide, in post-menopausal women. European Journal of Endocrinology, 136, 483-487.
2. Bowers, C.Y., Momany, F.A., Reynolds, G.A., & Hong, A. (1984) On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, 114, 1537-1545.
3. Bowers, C.Y., Reynolds, G.A., Durham, D., Barrera, C.M., Pezzoli, S.S., & Thorner, M.O. (1990) Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Journal of Clinical Endocrinology and Metabolism, 70, 975-982.
4. Chapman, I.M., Bach, M.A., Van Cauter, E., Farmer, M., Krupa, D., Taylor, A.M., Schilling, L.M., Cole, K.Y., Skiles, E.H., Pezzoli, S.S., Hartman, M.L., Veldhuis, J.D., Gormley, G.J., & Thorner, M.O. (1996) Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism, 81, 4249-4257.
5. Crave, J.C., Lejeune, H., Brebant, C., Baret, C., & Pugeat, M. (1995) Differential effects of insulin and insulin-like growth factor I on the production of plasma steroid-binding globulins by human hepatoblastoma-derived (Hep G2) cells. Journal of Clinical Endocrinology and Metabolism, 80, 1283-1289.
6. Frieboes, R.M., Murck, H., Mater Maier, P., Schier, T., Holsboer, F., & Steiger, A. (1995) Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology, 61, 584-589.
7. Ghigo, E., Arvat, E., Gianotti, L., Grottoli, S., Rizzi, G., Ceda, G.P., Boghen, M.F, Deghenghi, R., & Camanni, F. (1996) Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. European Journal of Endocrinology, 135, 407-412.
8. Ghigo, E., Arvat, E., Gianotti, L., Imbimbo, B.P., Lenaerts, V., Deghenghi, R., & Camanni, F. (1994) Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. Journal of Clinical Endocrinology and Metabolism, 78, 693-698.
9. Ghigo, E., Arvat, E., Ramunni, J., Colao, A., Gianotti, L., Deghenghi, R., Lombardi, G., & Camanni, F. (1997) Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism, 82, 2439-2444.
10. Hayashi, S., Okimura, Y., Yagi, H., Uchiyama, T., Takeshima, Y., Shakutsui, S., Oohashi, S., Bowers, C.Y., & Chihara, K. (1991) Intranasal administration of His-D-Trp-Ala-Trp-D-Phe-LysNH2 (growth hormone releasing peptide) increased plasma growth hormone and insulin-like growth factor-I levels in normal men. Endocrinology Japan, 38, 15-21.
11. Ilson, B.E., Jorkasky, D.K., Curnow, R.T., & Stote, R.M. (1989) Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. Journal of Clinical Endocrinology and Metabolism, 69, 212-214.
12. Imbimbo, B.P., Mant, T., Edwards, M., Amin, D., Dalton, N., Boutignon, F., Lenaerts, V., Wuthrich, P., & Deghenghi, R. (1994) Growth hormone-releasing activity of hexarelin in humans. A dose-response study. European Journal of Clinical Pharmacology, 46, 421-425.
13. Kollerup, G., Thamsborg, G., Bhatia, H., & Sorensen, O.H. (1992) Quantitation of urinary hydroxypyridinium cross-links from collagen by high-performance liquid chromatography. Scandinavian Journal of Clinical Laboratory Investigation, 52, 657-662.
14. Korbonits, M., Trainer, P.J., & Besser, G.M. (1995) The effect of an opiate antagonist on the hormonal changes induced by hexarelin. Clinical Endocrinology, 43, 365-371.
15. Laron, Z., Bowers. C.Y, Hirsch, D., Almonte, A.S., Pelz, M., Keret, R., & Gil Ad, I. (1993) Growth hormone-releasing activity of growth hormone-releasing peptide-I (a synthetic heptapeptide) in children and adolescents. Acta Endocrinologica (Copenh), 129, 424-426.
16. Laron, Z., Frenkel, J., Gil Ad, I., Klinger, B., Lubin, E., Wuthrich, P., Boutignon, F., Lengerts, V., & Deghenghi, R. (1994) Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin). Clinical Endocrinology, 41, 539-541.
17. Massoud, A.F., Hindmarsh, P.C., & Brook, C.G. (1996) Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. Journal of Clinical Endocrinology and Metabolism, 81, 4338-4341.
18. Rahim, A., O'Neill, P.A., Shalet, S.M. (1998) Growth hormone (GH) status during long-term hexarelin therapy. Journal of Clinical Endocrinology and Metabolism, 83, 1644-1649.
19. Rodriguez-Arnao, J., Perry, L., Besser, G.M., & Ross, R.J. (1996) Growth hormone treatment in hypopituitary GH deficient adults reduces circulating cortisol levels during hydrocortisone replacement therapy. Clinical Endocrinology, 45, 33-37.
20. Svensson, J., Lönn, L., Jansson, J.-O., Murphy, G., Wyss, D., Krupa., D., Cerchio, K., Polvino, W., Gertz, B., Boseaus, I., Sjöström, L., & Bengtsson, B.-Å.(1997) Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology and Metabolism, 83, 362-369.
21. Weaver, J.U., Thaventhiran, L., Noonan, K., Burrin, J.M., Taylor, N.F., Norman M.R. & Monson, J.P. (1994) The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults. Clinical Endocrinology, 41, 639-648.